Meds A-Z
Amoxicillin
Detailed information about Amoxicillin
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For treatment of the following infections in dogs when caused by susceptible strains of organisms: BACTERIAL DERMATITIS due to Staphylococcus aureus , Streptococcus spp., Staphylococcus spp., and Escherichia coli . SOFT...
What it does:
For the treatment of susceptible strains of the organisms causing the following infections: Respiratory tract infections (tonsillitis, tracheobronchitis) due to Staphylococcus aureus , Streptococcus spp., Escherichia col...
When it's needed:
Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not slaughter animals during treatment or for 20 days afte...
Call your vet sooner if you notice:
- Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (2 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Amoxicillin
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Zoetis Inc.
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/65492 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200709 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- High: Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Dog | 1 |
Species coverage: Cat (16) Dog (16)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-048791
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 25 • Secondary summaries: 0
- Robamox®-V Tablets · SPL
- Biomox · SPL
- FOI Summary oA 200-709 Approved August 18, 2021.pdf · FOI
- Amoxicillin and Clavulanate Potassium for Oral Suspension · SPL
- FOI Summary oA 200-702 Approved April 23, 2021.pdf · FOI
- Amoxicillin and Clavulanate Potassium Tablets · SPL
- amoxi-tabs® · SPL
- amoxi-tabs® · SPL
- N055101_Supp_12_23_1997.pdf · FOI
- Clavamox® Drops · SPL
- Amoxi-Mast® · SPL
- FOI Summary oA 200-604 Approved October 20, 2021.pdf · FOI
- Clavacillin® · SPL
- UCM524262.pdf · FOI
- Clavacillin® · SPL
- Robamox®-V · SPL
- Biomox® · SPL
- Amoxi-Bol · SPL
- Amoxi-Doser · SPL
- Amoxi-Drop® Oral Suspension · SPL
- Amoxi-Inject (Cattle) · SPL
- Amoxi-Inject (Dogs and Cats) · SPL
- Amoxi-Sol · SPL
- Robamox®-V · SPL
- Robamox®-V Tablets · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1087/Robamox%C2%AE-V%20Tablets · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1086/Biomox · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11187 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11273/Amoxicillin%20and%20Clavulanate%20Potassium%20for%20Oral%20Suspension · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/10753 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10819/Amoxicillin%20and%20Clavulanate%20Potassium%20Tablets · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1021/amoxi-tabs%C2%AE · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1031/amoxi-tabs%C2%AE · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1953 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/973/Clavamox%C2%AE%20Drops · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:03 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0061-8128-01 | 0061 | - | |
| 11695-6991-1 | 11695 | - | |
| 11695-6992-1 | 11695 | - | |
| 11695-6993-1 | 11695 | - | |
| 11695-6994-1 | 11695 | - | |
| 11695-7007-1 | 11695 | - | |
| 13744-540-01 | 13744 | - | |
| 13744-541-01 | 13744 | - | |
| 13744-542-01 | 13744 | - | |
| 13744-543-01 | 13744 | - | |
| 17033-440-07 | 17033 | - | |
| 17033-440-21 | 17033 | - | |
| 17033-441-07 | 17033 | - | |
| 17033-441-21 | 17033 | - | |
| 17033-442-07 | 17033 | - | |
| 17033-442-21 | 17033 | - | |
| 17033-443-07 | 17033 | - | |
| 17033-443-21 | 17033 | - | |
| 17033-451-15 | 17033 | - | |
| 32903-122-25 | 32903 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI Summary oA 200-709 Approved August 18, 2021.pdf
• FOI summary • Official
• April 10, 2024
FDA FOI summary for application 200709
-
FOI Summary oA 200-702 Approved April 23, 2021.pdf
• FOI summary • Official
• Dec. 12, 2023
FDA FOI summary for application 200702
-
N055101_Supp_12_23_1997.pdf
• FOI summary • Official
• Jan. 12, 2023
FDA FOI summary for application 55101
-
FOI Summary oA 200-604 Approved October 20, 2021.pdf
• FOI summary • Official
• July 25, 2022
FDA FOI summary for application 200604
-
UCM524262.pdf
• FOI summary • Official
• March 29, 2022
FDA FOI summary for application 200592
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. … (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Elevated alanine aminotransferase (ALT), D… (Official, 2026-02-12)
- usage: For the treatment of susceptible strains of the organisms causing the following infections: Respiratory tract infections (tonsillitis, tracheobronchitis) due t… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Robamox®-V Tablets Biomox
RX
Amoxicillin Trihydrate
Tablet
• Oral
|
Virbac AH, Inc. | NADA 65492 | Approved | Jun 13, 2024 |
|
Amoxicillin and Clavulanate Potassium for Oral Suspension
RX
Amoxicillin Trihydrate Clavulanate Potassium
Suspension
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-709 | Approved | Apr 10, 2024 |
|
Amoxicillin and Clavulanate Potassium Tablets
RX
Amoxicillin Trihydrate Clavulanate Potassium
Tablet
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-702 | Approved | Dec 12, 2023 |
|
amoxi-tabs®
RX
Amoxicillin Trihydrate
Tablet
• Oral
|
Zoetis Inc. | NADA 55078 | Approved | Jul 10, 2023 |
|
amoxi-tabs®
RX
Amoxicillin Trihydrate
Tablet
• Oral
|
Zoetis Inc. | NADA 55081 | Approved | Jul 10, 2023 |
|
Clavamox® Drops
RX
Amoxicillin Trihydrate Clavulanate Potassium
Liquid
• Oral
|
Zoetis Inc. | NADA 55101 | Approved | Jan 12, 2023 |
|
Amoxi-Mast®
RX
Amoxicillin Trihydrate
Liquid
• Intramammary
|
Intervet, Inc. | NADA 55100 | Approved | Dec 16, 2022 |
|
Clavacillin®
RX
Amoxicillin Trihydrate Clavulanate Potassium
Suspension
• Oral
|
Dechra Veterinary Products LLC | ANADA 200-604 | Approved | Jul 25, 2022 |
|
Clavacillin®
RX
Amoxicillin Trihydrate Clavulanate Potassium
Tablet
• Oral
|
Dechra Veterinary Products LLC | ANADA 200-592 | Approved | Mar 29, 2022 |
|
Robamox®-V Biomox®
RX
Amoxicillin Trihydrate
Liquid (Suspension)
• Oral
|
Virbac AH, Inc. | NADA 65495 | Approved | Oct 9, 2019 |
|
Amoxi-Bol
RX
Amoxicillin Trihydrate
Bolus
• Oral
|
Zoetis Inc. | NADA 55087 | Approved | Jun 1, 2016 |
|
Amoxi-Doser
RX
Amoxicillin Trihydrate
Liquid (Suspension)
• Oral
|
Zoetis Inc. | NADA 55080 | Approved | Jun 1, 2016 |
|
Amoxi-Drop® Oral Suspension
RX
Amoxicillin Trihydrate
Liquid (Suspension)
• Oral
|
Zoetis Inc. | NADA 55085 | Approved | Jun 1, 2016 |
|
Amoxi-Inject (Cattle)
RX
Amoxicillin Trihydrate
Liquid (Suspension)
• Subcutaneous, Intramuscular
|
Zoetis Inc. | NADA 55089 | Approved | Jun 1, 2016 |
|
Amoxi-Inject (Dogs and Cats)
RX
Amoxicillin Trihydrate
Liquid (Suspension)
• Subcutaneous, Intramuscular
|
Zoetis Inc. | NADA 55091 | Approved | Jun 1, 2016 |
|
Amoxi-Sol
RX
Amoxicillin Trihydrate
Liquid (Solution)
• Oral
|
Zoetis Inc. | NADA 55088 | Approved | Jun 1, 2016 |
|
Robamox®-V
RX
Amoxicillin Trihydrate
Liquid (Suspension)
• Oral
|
Zoetis Inc. | NADA 141-004 | Approved | Jun 1, 2016 |
|
Robamox®-V Tablets
RX
Amoxicillin Trihydrate
Tablet
• Oral
|
Zoetis Inc. | NADA 141-005 | Approved | Jun 1, 2016 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For treatment of the following infections in dogs when caused by susceptible strains of organisms:
BACTERIAL DERMATITIS due to Staphylococcus aureus, Streptococcus spp., Staphylococcus spp., and Escherichia coli.
SOFT TISSUE INFECTIONS (abscesses, wounds, lacerations) due to Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Staphylococcus spp.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
The recommended dosage is 6.25 mg/lb of body weight twice a day.
For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
The recommended dosage is 62.5 mg twice a day.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of susceptible strains of the organisms causing the following infections:
Respiratory tract infections (tonsillitis, tracheobronchitis) due to Staphylococcus aureus, Streptococcus spp., Escherichia coli, and Proteus mirabilis.
Genitourinary tract infections (cystitis) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
Gastrointestinal tract infections (bacterial gastroenteritis) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
Bacterial dermatitis due to Staphylococcus aureus, Streptococcus spp., and Proteus mirabilis.
Soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
The recommended dosage is 5 mg/lb of body weight twice a day. Dosage should be continued for 5–7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy.
For the treatment of susceptible strains of the organisms causing the following infections:
Upper respiratory tract infections due to Staphylococcus aureus, Streptococcus spp., and E. coli.
Genitourinary tract infections (cystitis) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
Gastrointestinal tract infections due to E. coli.
Skin and soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Pasteurella multocida.
The recommended dosage is 50 mg (5–10 mg/lb) once a day. Dosage should be continued for 5–7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of susceptible strains of the organisms causing the following infections:
Respiratory tract infections (tonsillitis, tracheobronchitis) due to Staphylococcus aureus, Streptococcus spp., Escherichia coli, and Proteus mirabilis.
Genitourinary tract infections (cystitis) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
Gastrointestinal tract infections (bacterial gastroenteritis) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
Bacterial dermatitis due to Staphylococcus aureus, Streptococcus spp., and Proteus mirabilis.
Soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
The recommended dosage is 5 mg/lb of body weight twice a day. Dosage should be continued for 5–7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy.
For the treatment of susceptible strains of the organisms causing the following infections:
Upper respiratory tract infections due to Staphylococcus aureus, Streptococcus spp., and E. coli.
Genitourinary tract infections (cystitis) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Proteus mirabilis.
Gastrointestinal tract infections due to E. coli.
Skin and soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus, Streptococcus spp., E. coli, and Pasteurella multocida.
The recommended dosage is 50 mg (5–10 mg/lb) once a day. Dosage should be continued for 5–7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Clavamox Drops are indicated in the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease.
The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5–7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
Clavamox Drops are indicated in the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the organisms to Clavamox. Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated.
The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5–7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10–14 days or longer. The maximum duration of treatment should not exceed 30 days.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
125 mg (100 mg amoxicillin, 25 mg clavulanic acid)
250 mg (200 mg amoxicillin, 50 mg clavulanic acid)
375 mg (300 mg amoxicillin, 75 mg clavulanic acid)
For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
The recommended dosage is 62.5 mg twice a day.Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase- producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Amoxicillin trihydrate and clavulanate potassium tablets have been shown to be clinically effective for treating cases of canine periodontal disease.
The recommended dosage is 6.25 mg/lb of body weight twice a day.Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Treatment of bacterial dermatitis due to Staphylococcus aureus, Streptococcus species, Staphylococcus species, and Escherichia coli; and soft tissues infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus, Streptococcus species, Escherichia coli, Proteus mirabilis, Staphylococcus species.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
- Robamox®-V Tablets (ZIP)
- Biomox (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of the following:
Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
FDA page: Open in Animal Drugs @ FDA
-
Summary
Amoxicillin and Clavulanate Potassium Tablets are indicated in the treatment of:
Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
FDA page: Open in Animal Drugs @ FDA
- amoxi-tabs® (ZIP)
FDA page: Open in Animal Drugs @ FDA
- amoxi-tabs® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Adds claims for periodontal infections in dogs.
- Clavamox® Drops (ZIP)
FDA page: Open in Animal Drugs @ FDA
- Amoxi-Mast® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of:
Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
- Clavacillin® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM524262.pdf
Summary
For the treatment of: Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non- ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp. and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Amoxicillin trihydrate and clavulanate potassium tablets have been shown to be clinically effective for treating cases of canine periodontal disease. Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non- ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
- Clavacillin® (ZIP)
FDA page: Open in Animal Drugs @ FDA
- Robamox®-V (ZIP)
- Biomox® (ZIP)
FDA page: Open in Animal Drugs @ FDA
- Amoxi-Bol (ZIP)
FDA page: Open in Animal Drugs @ FDA
- Amoxi-Doser (ZIP)
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
- Amoxi-Inject (Cattle) (ZIP)
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
- Amoxi-Sol (ZIP)
FDA page: Open in Animal Drugs @ FDA
- Robamox®-V (ZIP)
FDA page: Open in Animal Drugs @ FDA
- Robamox®-V Tablets (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of susceptible strains of the organisms causing the following infections: Respiratory tract infections (tonsillitis, tracheobronchitis) due to Staphylococcus aureus , Streptococcus spp., Escherichia coli , and Proteus mirabilis . Genitourinary tract infections (cystitis) due to Staphylococcus aureus , Streptococcus spp., E. coli , and Proteus mirabilis . Gastrointestinal tract infections (bacterial gastroenteritis) due to Staphylococcus aureus , Streptococcus spp., E. coli , and Proteus mirabilis . Bacterial dermatitis due to Staphylococcus aureus , Streptococcus spp., and Proteus mirabilis . Soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus , Streptococcus spp., E. coli , and Proteus mirabilis . For the treatment of susceptible strains of the organisms causing the following infections: Upper respiratory tract infections due to Staphylococcus aureus , Streptococcus spp., and E. coli . Genitourinary tract infections (cystitis) due to Staphylococcus aureus , Streptococcus spp., E. coli , and Proteus mirabilis . Gastrointestinal tract infections due to E. coli . Skin and soft tissue infections (abscesses, lacerations, and wounds) due to Staphylococcus aureus , Streptococcus spp., E. coli , and Pasteurella multocida . For the treatment of baby pigs under 10 pounds for porcine colibacillosis caused by Escherichia coli susceptible to amoxicillin.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Spaniel - King Charles Cavalier, Female, 3 year, 8.98 kilogram • Drug: MSK, Unknown • Reactions: Vomiting, Lying down, Decreased appetite, Bloody diarrhoea • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055888
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 3.00 Year
- Weight: 8.980 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Dog, Sheepdog - Old English (Bobtail), Male, 4 year, 37.8 kilogram • Drug: MSK, Unknown • Reactions: Malaise, Gastric ulcer, Peritonitis, Fluid in abdomen NOS, Fluid in abdomen NOS… • Outcome: Euthanized
- Report ID: DEU-USFDACVM-2025-DE-000039
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 4.00 Year
- Weight: 37.800 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Dog, Terrier - Bull, Male, 10 year, 32.38 kilogram • Drug: MSK, Powder, for solution, Unknown • Reactions: Elevated alanine aminotransferase, Diarrhea, Elevated serum alkaline phosphatase, Elevated gamma-glutamyl transferase, Abnormal ultrasound finding… • Outcome: Euthanized
- Report ID: USA-USFDACVM-2025-US-054535
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 10.00 Year
- Weight: 32.380 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Powder, for solution
Dog, Spaniel - Springer (unspecified), Male, 8 year, 23.587 kilogram • Drug: MSK, Tablet, Oral, Dose: 400 Milligram per dose, Frequency: 12 per hour • Reactions: Mouth pain, Swollen lymph node, Facial swelling (possible allergy), Conjunctival oedema • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054312
- Serious AE: No
- Treated For AE: Yes
- Sex: Male
- Age: 8.00 Year
- Weight: 23.587 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 400 Milligram per dose
- Frequency: 12 per hour
Cat, Domestic Shorthair, Male, 7 week, 0.363 kilogram • Drug: MSK, Solution/drops, Oral, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Death • Outcome: Died
- Report ID: USA-USFDACVM-2025-US-052904
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 7.00 Week
- Weight: 0.363 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution/drops
- Dose: 1 dose per animal
- Frequency: 1 per day
Dog, Sheepdog - Shetland, Female, 12 year, 9.707 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Haematuria, Proteinuria, Pyuria • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-051593
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 12.00 Year
- Weight: 9.707 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Unassigned
Cat, Cat (unknown), Male, 5.21 kilogram • Drug: MSK, Unknown • Reactions: Diarrhea • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-052336
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Weight: 5.210 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Cat, Maine Coon, Male, 10 year, 4.944 kilogram • Drug: MSK, Dose: 100 Milligram per other, Frequency: 12 per hour • Reactions: Tiredness (lethargy), Loss of appetite, Dehydration, Ketonuria, Elevated total bilirubin… • Outcome: Euthanized
- Report ID: USA-USFDACVM-2025-US-052186
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 10.00 Year
- Weight: 4.944 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Dose: 100 Milligram per other
- Frequency: 12 per hour
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.